1. Home
  2. RNAZ vs ATCH Comparison

RNAZ vs ATCH Comparison

Compare RNAZ & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNAZ
  • ATCH
  • Stock Information
  • Founded
  • RNAZ 2016
  • ATCH 2022
  • Country
  • RNAZ United States
  • ATCH United States
  • Employees
  • RNAZ N/A
  • ATCH N/A
  • Industry
  • RNAZ Biotechnology: Pharmaceutical Preparations
  • ATCH
  • Sector
  • RNAZ Health Care
  • ATCH
  • Exchange
  • RNAZ Nasdaq
  • ATCH Nasdaq
  • Market Cap
  • RNAZ 8.7M
  • ATCH 9.0M
  • IPO Year
  • RNAZ 2021
  • ATCH N/A
  • Fundamental
  • Price
  • RNAZ $15.00
  • ATCH $0.37
  • Analyst Decision
  • RNAZ Strong Buy
  • ATCH
  • Analyst Count
  • RNAZ 1
  • ATCH 0
  • Target Price
  • RNAZ $280.00
  • ATCH N/A
  • AVG Volume (30 Days)
  • RNAZ 13.8K
  • ATCH 121.0M
  • Earning Date
  • RNAZ 11-13-2025
  • ATCH 11-14-2025
  • Dividend Yield
  • RNAZ N/A
  • ATCH N/A
  • EPS Growth
  • RNAZ N/A
  • ATCH N/A
  • EPS
  • RNAZ N/A
  • ATCH 0.14
  • Revenue
  • RNAZ N/A
  • ATCH $10,856,612.00
  • Revenue This Year
  • RNAZ N/A
  • ATCH N/A
  • Revenue Next Year
  • RNAZ N/A
  • ATCH N/A
  • P/E Ratio
  • RNAZ N/A
  • ATCH $2.97
  • Revenue Growth
  • RNAZ N/A
  • ATCH 171.31
  • 52 Week Low
  • RNAZ $6.15
  • ATCH $0.14
  • 52 Week High
  • RNAZ $739.20
  • ATCH $26.94
  • Technical
  • Relative Strength Index (RSI)
  • RNAZ 84.37
  • ATCH 45.73
  • Support Level
  • RNAZ $10.32
  • ATCH $0.45
  • Resistance Level
  • RNAZ $12.28
  • ATCH $0.53
  • Average True Range (ATR)
  • RNAZ 0.87
  • ATCH 0.13
  • MACD
  • RNAZ 0.57
  • ATCH -0.06
  • Stochastic Oscillator
  • RNAZ 91.34
  • ATCH 0.38

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

About ATCH AtlasClear Holdings Inc. Common Stock

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

Share on Social Networks: